Many nonpeptide antagonists of the gonadotropin-releasing hormone (GnRH) receptor, as well as other drug targets, possess a broad range of dissociation kinetic rate constants. Current methods to accurately define kinetic rate parameters such as K on and K off are time and labor intensive, prompting the development of a screening assay to identify slowly dissociating compounds for follow-up rate constant determination. The authors measured inhibition binding constants (K i ) for GnRH receptor antagonists after 30 min and 10 h of incubation and observed several compounds with markedly decreased K i values over time (Ki 30 min /Ki 10 h > 6). They used scintillation proximity assay technology to perform these binding experiments because this homogeneous assay does not have a fixed termination end point as does filtration binding, permitting successive readings to be taken from the same assay plate over an extended period of time. They also used a quantitative method of kinetic rate analysis to confirm that a large disparity between a compound's K i value at 30 min and 10 h could identify compounds that dissociate slowly. Thus, the K i ratio can be used to screen for and select compounds to test using more quantitative, albeit lower throughput methods to accurately define kinetic rate constants. (Journal of Biomolecular Screening 2007:235-239) 
INTRODUCTION
M ANY GROUPS ARE DEVELOPING nonpeptide smallmolecule receptor antagonists to the gonadotropinreleasing hormone (GnRH) receptor in an attempt to provide a controlled functional blockade of the receptor and to alleviate the need for repeated peptide injections. [1] [2] [3] The elucidation of the mechanism of some commercially available drugs directed at multiple targets suggests that compounds with slow dissociation rates may have improved clinical efficacy over typical competitive antagonists. [4] [5] [6] [7] [8] [9] [10] Our recent observation that GnRH receptor antagonists are characterized by a wide range of kinetic rate constants provided the impetus for further investigation of compounds based on their receptor binding kinetics. 11 Methods to ascertain the kinetic rate constants of unlabeled compounds are difficult and low throughput. Therefore, a high-throughput estimation of the kinetic parameters (specifically the dissociation rate) of novel molecular entities is desirable. 12 This led us to develop a screening strategy to identify slowly dissociating nonpeptide GnRH antagonists that can be selected for follow-up kinetic rate determination.
Here we describe a modification of classic competition binding assays to identify slowly dissociating nonpeptide GnRH receptor antagonists using scintillation proximity assay (SPA) technology. 13 The theory behind this method is based on the observation that compound dose-response curves will shift over time until the radioligand, compound, and receptor have reached a state of equilibrium. By definition, equilibrium is reached when both the radiolabel and test compound are allowed to incubate with the receptor for 4 times longer than the dissociation half-life of the slower species. 12 For example, if one of these entities has a dissociation half-life of 30 min, the competition binding assay would require 2 h of incubation to reach equilibrium and produce a kinetically accurate K i . For compounds with even slower dissociation rates (i.e., 12 h), it may take days for the reaction to achieve equilibrium. Until the point of equilibration, the doseresponse curves will shift closer to the curve indicative of true binding affinity. 14, 15 Therefore, slowly dissociating compounds will display a more pronounced shift in K i over time and will require a longer period of incubation to reach equilibrium.
In this study, compounds were assayed for their binding affinity to GnRH receptor containing membranes after 30 min and 10 h of incubation by recording the luminescent emission of the same assay plate in a CCD imager. We confirmed that the compounds with greatest disparity between K i values measured at 30 min and 10 h had the slowest dissociation rates using a quantitative method of kinetic rate analysis. 12 This time-dependent SPA methodology is a novel screening platform that can be applied to identify compounds with slow dissociation kinetics in high throughput and provides a more accurate affinity measurement for a given slow dissociating compound. The SPA assay platform also permits the use of 96-, 384-, and 1536-well formats to assay compounds for their binding affinity, well beyond the capacity limitations of typical 96-well filtration techniques.
MATERIALS AND METHODS

SPA competition radioligand binding
Wheatgerm agglutinin (WGA)-coupled polystyrene (PS) imaging beads (Amersham Biosciences, Piscataway, NJ) were used in our scintillation proximity assay, permitting whole-plate light imaging with a CCD imaging system, as used by Viewlux (PerkinElmer Life Sciences, Boston, MA). The Viewlux was set to measure luminescence for 300 sec using a 613-nm filter to capture the red-shifted emission of the imaging beads and programmed to record at 30-min intervals for 18 h. Assay viability was assessed at each time point by calculating the Z´ score and determining the goodness of fit of dose-response curves at each time interval. Integrity of the receptor and radiolabel was monitored by saturation analysis measured at each time point to ensure a consistent K d . The SPA assay typically produced reliable binding data up to 16 h of incubation. For the purposes of this report, we recorded luminescence at 30 min and at 10 h of assay incubation. Time intervals earlier than 30 min were not sufficient enough to yield a robust assay signal, and although the assay was viable up to 16 h, we observed a significant shift in dose-response curves at 10 h and selected this as our end time point. The optimal membrane/SPA bead ratio was determined for each membrane preparation and was typically 40 µg membrane/ 0.5 mg bead per well. Reactions were performed in singlet and consisted of 25 µL unlabeled compound at indicated concentrations; 25 µL radiolabeled [ 125 I]-His 5 , D-Tyr 6 GnRH ligand (~300 pM, 2200 Ci/mmol; PerkinElmer Life Sciences); and 50-µL membrane/SPA bead added sequentially in assay buffer (10 mM HEPES, 150 mM NaCl, 0.1% bovine serum albumin [BSA;
Fraction V], pH 7.5) to low binding 96-well plates (Corning, Palo Alto, CA). SPA beads and membrane (rat basophilic leukemia [RBL] cells stably expressing human GnRH-R) were allowed to preincubate for 2 h prior to addition to compound and radiolabel. The complete reaction was briefly shaken and then allowed to settle at room temperature in the Viewlux. The amount of bound radioligand was determined at the indicated time intervals. Cell membrane fractions were prepared as previously described and resuspended in assay buffer. 16 
Analysis of dose-response curves
A single-site binding model fit best for all displacement binding experiments, as determined by a partial F test (p > 0.05). Dose-response curves were rejected when the fit of the data dropped below acceptability (r 2 < 0.9). Dose-response curves for both time points of all compounds tested were normalized to zero and 100% specific binding, and K i values were calculated using the Cheng-Prusoff equation with a sigmoidal dose-response fit using Prism 4.0 software (GraphPad Software, San Diego, CA) using K d values of 0.7 nM for [ 125 I]-His 5 , D-Tyr 6 GnRH, as determined from saturation binding experiments. Hill slopes for all curves routinely ranged from -0.8 to -1.1.
Nonequilibrium kinetic association experiments
Dissociation kinetic rate constants were determined exactly as described previously. 11
RESULTS and DISCUSSION
SPA competition binding
We employed the SPA format to measure the binding affinity of 78 nonpeptide GnRH receptor antagonists. This assay platform permits continuous readout of a single experiment over time without terminating the assay. Compounds representing structurally distinct chemical series were dosed by serial dilution for 12 concentrations on 96-well plates followed by addition of [ 125 I]-His 5 , D-Tyr 6 GnRH. Competition binding was initiated by the addition of GnRH-R-containing membranes precoupled to SPA beads, and luminescence was recorded after 30 min and 10 h of incubation (see Materials and Methods). Typical doseresponse curves for 2 compounds can be seen in Figure 1A ,B. The Z´ score determined for a typical assay, recorded at 30 min and 10 h, was 0.63 and 0.62, respectively, representing very robust assay conditions. The K i values for these compounds, measured at 90 min in the SPA assay, were not significantly different (p < 0.0001) from those obtained from standard filtration binding terminated after 90 min (data not shown). The ability to measure binding affinities at 2 time points from the same assay plate removes intraexperiment variability apparent if performing 2 separate filtration experiments. The difference between affinities at 30 min and 10 h can then be considered more dependent on true change in apparent affinity rather than assay variability. Furthermore, assay viability over time more than doubled for SPA compared with filtration binding, perhaps due to stabilization of the receptor-membrane complex when coupled to a solid support bead (data not shown). A loss of signal for filtration experiments typically occurred after 4 h of incubation. A tritiated small-molecule tracer ligand may extend the time course of the SPA assay even further by replacing a labile peptide radiolabel with a more stable small-molecule radiolabel.
The potency of the compound in Figure 1A did not change significantly from 30 min to 10 h (8.9 nM and 7.4 nM, respectively), indicative of equilibration between the compound, the radiolabel, and the receptor (Ki 30 min /Ki 10 h = 1.2). Nor was there a change in the K i value for cold His 5 , D-Tyr 6 GnRH over this time period (data not shown), consistent with the assumption that the unlabeled peptide exhibits the same kinetic parameters as the radiolabeled analog. The compound shown in Figure 1B caused the most severe shift in dose-response curves measured at 30 min and 10 h, resulting in the greatest change in apparent affinity for any compound tested (~1.5 log orders) (2.0 nM and 0.087 nM, respectively; Ki 30 min /Ki 10 h = 22.9). Importantly, this compound, which previously may have been reported as having a 2 nM affinity at 30 min, now is revealed to bind with at least a 0.087 nM affinity. An advantage this technique may offer is that binding affinities for structure activity relationship (SAR) determination (measurements recorded after 90 min of incubation, for instance) could be performed simultaneously to this methodology by programming the plate reader to record at any desired time points. It is not suggested that this be used because, in fact, compounds not permitted to attain equilibrium in competition binding assays under the time frame of the experiment will provide an underestimated affinity, potentially skewing the SAR, as evidenced by the data shown herein. The ratios of the K i value (in nM) measured at 30 min, divided by the K i value measured at 10 h, were determined for all 78 compounds and are shown in Figure 1C . Seven compounds (9% of total) were found to have a Ki 30 min /Ki 10 h ratio of 6 or greater, whereas the K i values for the remaining 71 compounds (91%) varied by less than 6-fold between the 2 time points. For our purposes, Ki 30 min /Ki 10 h > 6 was selected because this ratio detected 10% of compounds.
Nonequilibrium association kinetics
We quantitatively determined the kinetic rate constants of 12 compounds (5 with Ki 30 min /Ki 10 h > 6 and 7 with Ki 30 min /Ki 10 h < 6) using a nonequilibrium method of association kinetics. 12 This method describes the kinetics of competitive radioligand binding as predicted by the law of mass action. The association rate constant of each compound was quantified and, although relevant when calculating binding constants, is not as clearly linked to clinical efficacy as is the dissociation rate, 4-10 which is the focus of this report. The dissociation half-life (t 1/2 ) of these compounds ranged from 12 min to greater than 12 h. As depicted in Figure 2 , all 5 compounds with Ki 30 min /Ki 10 h > 6 possessed a dissociation half-life of 1 h or greater. Six of 7 compounds with Ki 30 min /Ki 10 h < 6 possessed a dissociation half-life of less than 1 h, indicating that the selection criteria chosen for our screen resulted in zero false positives and 1 false negative. The nonequilibrium association kinetic method confirmed that using SPA to generate a ratio of K i values at different time points is a valid screening tool for the selection of slowly dissociating compounds. This methodology might also select compounds that are irreversible inhibitors, of which the follow-up kinetic rate evaluation would decipher. In fact, both slowly dissociating compounds and irreversible inhibitors appear insurmountable in functional assays because each has a prolonged receptor residence that serves to essentially remove the available receptor from the population. 11, 17 It is out of the scope of this report to define slow dissociation as t 1/2 greater than 1 h. This time constraint was selected as the median half-life time for the compounds tested. Had we chosen a time constraint to define slowly dissociating as 65 min or slower, in fact, the lone reported false negative would have been identified as rapidly dissociating, and we could report zero false negatives in our screen. Investigators choosing to use this methodology to identify slowly dissociating compounds are suggested to select their criteria empirically with their assay to provide the greatest efficiency in selection. Furthermore, the stability and solubility of compounds in experiments of extended duration is difficult to assess, and such degradation or dissolution has the potential to lead to the reporting of false-negative results.
High-Throughput Kinetics
We plotted the dissociation rate constants determined by the nonequilibrium association kinetic method against the ratio of Ki 30 min /Ki 10 h obtained from the SPA assay to determine if our screening methodology is predictive of off-rate parameters (Fig. 3) . A trend was clearly evident from our data, suggesting that the faster dissociating compounds had the smallest change in apparent affinity, whereas the slower dissociators had the largest change, resulting in the largest leftward shift in doseresponse curves over time. The upper-right quadrant in this figure represents the 5 compounds with Ki 30 min /Ki 10 h > 6 and t 1/2 slower than 1 h (dissociation rate constant < 0.012). The lowerleft quadrant represents the 6 compounds with Ki 30 min /Ki 10 h < 6 and t 1/2 faster than 1 h. The false negative is indicated in the figure.
It is not suggested that a Ki 30 min /Ki 10 h ratio can be used quantitatively to calculate a dissociation rate constant, but it is evident that this ratio is predictive of overall speed of the receptor dissociation. We recommend quantitatively determining the kinetic rate constants to rank order compounds by dissociation rates. We have shown here, however, that this rapid screen determining a Ki 30 min /Ki 10 h ratio is a valid tool for selecting compounds to be assessed quantitatively using the lower throughput assays described by Motulsky et al. 12 
CONCLUSION
In light of recent discussions in the literature correlating slow dissociation kinetic rates with clinical efficacy, this report provides a timely description of a method providing utility to rapidly identify compounds with such characteristics. [4] [5] [6] [7] [8] [9] [10] This method is amenable for testing thousands of compounds with relative ease. The capacity of filtration techniques is generally limited to 96-well format, whereas SPA can be formatted into 384-and 1536-well formats, providing that a sufficient assay signal is produced. Repeated measurements of SPA assays reduce the time and resources required by filtration, remove intraexperiment variability, and can potentially increase assay viability, leading to more accurate affinity values relative to filtration techniques. This report has validated a high-throughput method as a tool to screen compounds for kinetic parameters and, in combination with nonequilibrium association kinetics, may be very useful for obtaining pharmacodynamic properties of many potential drugs with improved clinical efficacy.
